Tx Dew. I believe these results are excellent.
from PR:
"Specifically, in the ongoing 300 mg dose cohort, the mean overall decline from baseline is currently ≥2.8 log10 IU/mL, with ≥2.9 and 2.5 log10 IU/mL mean declines in HBeAg positive and negative patients, respectively. Maximal viral load declines of 3.6 to 4.0 log10 IU/mL were observed in certain HBeAg negative patients treated at all dose levels (100 to 400 mg). The company intends to report complete results from this study at a scientific conference later this year."
as mr Mkt's response, well ... lol same thing happened to Selb a few days ago with data update on the gout trial and today well the stock went back up. So i don't pay attention to price gyration too much because mr mkt is made up mostly of stock renters and further more price is always set at the margin. the data will speak for themselves, later lol
i must say, asmb price correction may have to do with its current valuation and not necessarily reflect the probability of curing hepB
Market Data 
Markets 
AI
